drugset / Trial / NCT04301765

Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency

NCT04301765

Phase 2 Active not recruiting 230 enrolled Seattle Institute for Biomedical and Clinical Research
RandomizedParallel-groupQuadruple-blindSupportive care

Summary

This is a large randomized, double-blind, placebo-controlled trial to determine the efficacy of testosterone replacement on cancer-related fatigue in older men with solid or hematologic (blood) cancer who report fatigue and have low testosterone levels.

Timeline

Start
2021-01-12
Primary completion
2026-11
Completion
2026-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Testosterone Small molecule 1.62 %